oxetorone
treatment of migraine; RN given refers to parent cpd; structure
Also Known As:
6-(3-dimethylamino-1-propylidene) benzofuro(2,3-e)-12H-benzo(b)oxepine fumarate; Nocertone; oxetorone fumarate; oxetorone fumarate, (E)-isomer
Networked: 13
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Bruneau, Chloé:
1 article
(02/2017)
|
2. | Deguigne, Marie:
1 article
(02/2017)
|
3. | Le Roux, Gaël:
1 article
(02/2017)
|
4. | Touré, Ali:
1 article
(02/2017)
|
5. | Turcant, Alain:
1 article
(02/2017)
|
6. | Azouz, M M:
1 article
(02/2010)
|
7. | Chatti, S:
1 article
(02/2010)
|
8. | Fathallah, N:
1 article
(02/2010)
|
9. | Descotes, Jacques:
1 article
(11/2006)
|
10. | Patat, Anne-Marie:
1 article
(11/2006)
|
Related Diseases
1. | Migraine Disorders (Migraine)
|
2. | Lymphocytic Colitis
|
3. | Poisoning
|
4. | Headache (Headaches)
|
5. | Ventricular Tachycardia
02/01/2017
- " Symptoms of moderate severity (PSS2 = drowsiness, hypertonia, myosis, convulsions, arterial hypotension, QRS widening, QTc prolongation) were observed following ingestion of more than 600 mg of oxetorone (median dose =1200 mg) and severe symptoms (PSS 3 = coma, convulsions, QTc prolongation, QRS widening, ventricular tachycardia, arterial hypotension, cardiogenic shock) were observed starting from 1800 mg (median dose =2700 mg). "
|
|
Related Drugs and Biologics